Please use this identifier to cite or link to this item:
https://doi.org/10.21256/zhaw-3749Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Wieser, Simon | - |
| dc.contributor.author | Riguzzi, Marco | - |
| dc.contributor.author | Pletscher, Mark | - |
| dc.contributor.author | Huber, Carola A. | - |
| dc.contributor.author | Telser, Harry | - |
| dc.contributor.author | Schwenkglenks, Matthias | - |
| dc.date.accessioned | 2018-06-18T09:01:43Z | - |
| dc.date.available | 2018-06-18T09:01:43Z | - |
| dc.date.issued | 2018 | - |
| dc.identifier.issn | 1618-7601 | de_CH |
| dc.identifier.issn | 1618-7598 | de_CH |
| dc.identifier.uri | https://digitalcollection.zhaw.ch/handle/11475/7015 | - |
| dc.description.abstract | In most countries, surprisingly little is known on how national healthcare spending is distributed across diseases. Single-disease cost-of-illness studies cover only a few of the diseases affecting a population and in some cases lead to untenably large estimates. The objective of this study was to decompose healthcare spending in 2011, according to Swiss National Health Accounts, into 21 collectively exhaustive and mutually exclusive major disease categories. Diseases were classified following the Global Burden of Disease Study. We first assigned the expenditures directly mapping from National Health Accounts to the 21 diseases. The remaining expenditures were assigned based on diagnostic codes and clues contained in a variety of microdata sources. Expenditures were dominated by non-communicable diseases with a share of 79.4%. Cardiovascular diseases stood out with 15.6% of total spending, followed by musculoskeletal disorders (13.4%), and mental and substance use disorders (10.6%). Neoplasms (6.0% of the total) ranked only sixth, although they are the leading cause of premature death in Switzerland. These results may be useful for the design of health policies, as they illustrate how healthcare spending is influenced by the epidemiological transition and increasing life expectancy. They also provide a plausibility check for single cost-of-illness studies. Our study may serve as a starting point for further research on the drivers of the constant growth of healthcare spending. | de_CH |
| dc.language.iso | en | de_CH |
| dc.publisher | Springer | de_CH |
| dc.relation.ispartof | The European Journal of Health Economics | de_CH |
| dc.rights | http://creativecommons.org/licenses/by/4.0/ | de_CH |
| dc.subject | Cost-of-illness | de_CH |
| dc.subject | Decomposition by disease | de_CH |
| dc.subject | Healthcare cost | de_CH |
| dc.subject | Healthcare expenditure | de_CH |
| dc.subject | National health account | de_CH |
| dc.subject | Switzerland | de_CH |
| dc.subject.ddc | 362.1041: Gesundheitsökonomie | de_CH |
| dc.title | How much does the treatment of each major disease cost? A decomposition of Swiss National Health Accounts | de_CH |
| dc.type | Beitrag in wissenschaftlicher Zeitschrift | de_CH |
| dcterms.type | Text | de_CH |
| zhaw.departement | School of Management and Law | de_CH |
| zhaw.organisationalunit | Winterthurer Institut für Gesundheitsökonomie (WIG) | de_CH |
| dc.identifier.doi | 10.21256/zhaw-3749 | - |
| dc.identifier.doi | 10.1007/s10198-018-0963-5 | de_CH |
| dc.identifier.pmid | 29470673 | de_CH |
| zhaw.funding.eu | No | de_CH |
| zhaw.issue | 8 | de_CH |
| zhaw.originated.zhaw | Yes | de_CH |
| zhaw.pages.end | 13 | de_CH |
| zhaw.pages.end | 1161 | de_CH |
| zhaw.pages.start | 1 | de_CH |
| zhaw.pages.start | 1149 | de_CH |
| zhaw.publication.status | publishedVersion | de_CH |
| zhaw.volume | 19 | de_CH |
| zhaw.publication.review | Peer review (Publikation) | de_CH |
| Appears in collections: | Publikationen School of Management and Law | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| 10.1007_s10198-018-0963-5.pdf | 1.2 MB | Adobe PDF |  View/Open |
Show simple item record
Wieser, S., Riguzzi, M., Pletscher, M., Huber, C. A., Telser, H., & Schwenkglenks, M. (2018). How much does the treatment of each major disease cost? A decomposition of Swiss National Health Accounts. The European Journal of Health Economics, 19(8), 1–1149. https://doi.org/10.21256/zhaw-3749
Wieser, S. et al. (2018) ‘How much does the treatment of each major disease cost? A decomposition of Swiss National Health Accounts’, The European Journal of Health Economics, 19(8), pp. 1–1149–13–1161. Available at: https://doi.org/10.21256/zhaw-3749.
S. Wieser, M. Riguzzi, M. Pletscher, C. A. Huber, H. Telser, and M. Schwenkglenks, “How much does the treatment of each major disease cost? A decomposition of Swiss National Health Accounts,” The European Journal of Health Economics, vol. 19, no. 8, pp. 1–1149–13–1161, 2018, doi: 10.21256/zhaw-3749.
WIESER, Simon, Marco RIGUZZI, Mark PLETSCHER, Carola A. HUBER, Harry TELSER und Matthias SCHWENKGLENKS, 2018. How much does the treatment of each major disease cost? A decomposition of Swiss National Health Accounts. The European Journal of Health Economics. 2018. Bd. 19, Nr. 8, S. 1–1149–13–1161. DOI 10.21256/zhaw-3749
Wieser, Simon, Marco Riguzzi, Mark Pletscher, Carola A. Huber, Harry Telser, and Matthias Schwenkglenks. 2018. “How Much Does the Treatment of Each Major Disease Cost? A Decomposition of Swiss National Health Accounts.” The European Journal of Health Economics 19 (8): 1–1149. https://doi.org/10.21256/zhaw-3749.
Wieser, Simon, et al. “How Much Does the Treatment of Each Major Disease Cost? A Decomposition of Swiss National Health Accounts.” The European Journal of Health Economics, vol. 19, no. 8, 2018, pp. 1–1149, https://doi.org/10.21256/zhaw-3749.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.